For several years, Dr. Scott Rocklage has achieved a tremendous success that has proven to be an inspiration to many individuals either in entrepreneurship or biochemical research. Currently, Dr. Scott serves as a managing partner at 5 AM Ventures. Read more: Scott Racklage | Bloomberg and Scott Racklage | Crunchbase
He started working there in 2003. Scott Rocklage is a doctor who is based in Boston and has a vast experience of almost three decades in the healthcare management. His experience and extensive scientific background have played a pivotal role in strengthening his background.
Backed up with his wealth expertise in both healthcare and scientific fields, together with the significant roles in his leadership skills, Dr. Scott has established an effective strategic leader in the domain of healthcare, venture capital, and pharmaceuticals.
Besides working as a managing partner at 5 AM Ventures where he is also a stakeholder, Dr. Scott serves as the chairman of the Boards of various companies including Semprus, Relypsa, and Achaogen.
He has also worked as chairman and CEO of Cubist Pharmaceuticals, served as the president and CEO of Nycomed Salutar and taken part in other leadership posts as R&D of Catalytica and Salutar.
Dr. Rocklage has expressed his excitement concerning the recent innovation in the diagnosis and cure of cancer that enables researchers to target specific cancer mutations, genotypes.
For this reason, cancer can now be treated using more than one technique. Scott rocklage adds that he is thrilled by the fact that the innovation will help in extending lives, if not saving. Therefore, the researchers will only advance the current advancement.
Dr. Scott’s success has made him be known as an extremely organized person in regards to calendaring, time management and prioritization. He as well targets to put more emphasis on people as the foundation of his ventures. According to the doctor, the selection process is vital to the success of any business.
He avers that significant failures in entrepreneurship start at the management level since the majority of people believe that performance evaluation and targets can change an individual’s morals and, hence, performance. Scott also notes that managers should not encourage underperformance.